in 2026 that nomination was withdrawn and BPC-157 was removed from Category 2, but the FDA has proposed against adding it to the 503A bulks list, so it remains unauthorized for compounding rather than cleared for it
How to use it: Apply after cleansing, either in a lightweight serum or as part of your nighttime routine
Normal collagen synthesis, elastin, proteoglycan, and glucosaminoglycan production in the skin
Through rational antigen design and adjuvant optimization, it may be possible to strategically induce trained immune states to support infection control, immune modulation, and even chronic disease intervention
L-Asparaginase, vincristine, and prednisone for induction of first remission in acute lymphocytic leukemia